Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blastomycosis | 8 | 2014 | 34 | 1.900 |
Why?
|
| Histoplasmosis | 6 | 2014 | 44 | 1.230 |
Why?
|
| Antifungal Agents | 9 | 2020 | 331 | 1.080 |
Why?
|
| Blastomyces | 4 | 2011 | 18 | 0.850 |
Why?
|
| Babesiosis | 1 | 2017 | 6 | 0.570 |
Why?
|
| Endemic Diseases | 2 | 2014 | 22 | 0.540 |
Why?
|
| Blood Transfusion | 1 | 2017 | 129 | 0.520 |
Why?
|
| Mycoses | 2 | 2020 | 155 | 0.470 |
Why?
|
| Antigens, Fungal | 2 | 2011 | 19 | 0.460 |
Why?
|
| Cecal Diseases | 1 | 2014 | 7 | 0.460 |
Why?
|
| Colonic Diseases | 1 | 2014 | 14 | 0.450 |
Why?
|
| Adrenal Insufficiency | 1 | 2014 | 18 | 0.450 |
Why?
|
| Ulcer | 1 | 2014 | 23 | 0.450 |
Why?
|
| Lung Diseases, Fungal | 3 | 2008 | 19 | 0.370 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2010 | 3 | 0.350 |
Why?
|
| Ixodes | 1 | 2010 | 6 | 0.340 |
Why?
|
| Amphotericin B | 3 | 2010 | 102 | 0.340 |
Why?
|
| Azoles | 1 | 2010 | 27 | 0.340 |
Why?
|
| Borrelia burgdorferi | 1 | 2010 | 31 | 0.330 |
Why?
|
| Lyme Disease | 1 | 2010 | 32 | 0.330 |
Why?
|
| HIV Infections | 1 | 2011 | 352 | 0.270 |
Why?
|
| Humans | 22 | 2020 | 50503 | 0.210 |
Why?
|
| Doxycycline | 2 | 2017 | 32 | 0.210 |
Why?
|
| Fatal Outcome | 2 | 2017 | 197 | 0.180 |
Why?
|
| Arkansas | 3 | 2020 | 1985 | 0.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2020 | 19 | 0.180 |
Why?
|
| Neoplasms | 2 | 2020 | 1251 | 0.170 |
Why?
|
| Histoplasma | 2 | 2011 | 23 | 0.160 |
Why?
|
| Male | 12 | 2017 | 25907 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1033 | 0.150 |
Why?
|
| Middle Aged | 8 | 2014 | 12611 | 0.150 |
Why?
|
| Sepsis | 1 | 2020 | 225 | 0.140 |
Why?
|
| Quinine | 1 | 2017 | 5 | 0.140 |
Why?
|
| Babesia | 1 | 2017 | 5 | 0.140 |
Why?
|
| Clindamycin | 1 | 2017 | 13 | 0.140 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 29 | 0.140 |
Why?
|
| Methicillin Resistance | 2 | 2007 | 17 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2014 | 5283 | 0.120 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 119 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 859 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 66 | 0.110 |
Why?
|
| Remission Induction | 1 | 2014 | 208 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 3226 | 0.100 |
Why?
|
| Coccidioidomycosis | 1 | 2012 | 6 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 137 | 0.090 |
Why?
|
| Cross Reactions | 1 | 2011 | 39 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 930 | 0.090 |
Why?
|
| Tomography | 1 | 2010 | 4 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2007 | 745 | 0.090 |
Why?
|
| North America | 1 | 2010 | 65 | 0.080 |
Why?
|
| Head | 1 | 2010 | 70 | 0.080 |
Why?
|
| United States | 3 | 2017 | 4955 | 0.080 |
Why?
|
| Radiography | 1 | 2010 | 485 | 0.080 |
Why?
|
| Fungemia | 2 | 2011 | 37 | 0.080 |
Why?
|
| Debridement | 1 | 2008 | 45 | 0.070 |
Why?
|
| Adult | 7 | 2010 | 13577 | 0.070 |
Why?
|
| Soft Tissue Infections | 1 | 2007 | 8 | 0.070 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2007 | 4 | 0.070 |
Why?
|
| Community-Acquired Infections | 1 | 2007 | 39 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 468 | 0.070 |
Why?
|
| Francisella tularensis | 1 | 2006 | 14 | 0.070 |
Why?
|
| Gentamicins | 1 | 2006 | 30 | 0.060 |
Why?
|
| Tularemia | 1 | 2006 | 19 | 0.060 |
Why?
|
| Optic Neuritis | 1 | 2006 | 21 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2006 | 137 | 0.060 |
Why?
|
| Triazoles | 1 | 2006 | 113 | 0.060 |
Why?
|
| Staphylococcal Infections | 2 | 2007 | 267 | 0.060 |
Why?
|
| Tetracyclines | 1 | 2005 | 9 | 0.060 |
Why?
|
| Staphylococcus aureus | 2 | 2007 | 321 | 0.060 |
Why?
|
| Health Facility Closure | 1 | 2004 | 3 | 0.060 |
Why?
|
| Female | 8 | 2012 | 27081 | 0.060 |
Why?
|
| DNA Fingerprinting | 1 | 2004 | 56 | 0.060 |
Why?
|
| Pseudomonas Infections | 1 | 2004 | 48 | 0.050 |
Why?
|
| Infection Control | 1 | 2004 | 47 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2004 | 72 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 32 | 0.050 |
Why?
|
| Onygenales | 1 | 2003 | 1 | 0.050 |
Why?
|
| Male Urogenital Diseases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Female Urogenital Diseases | 1 | 2003 | 5 | 0.050 |
Why?
|
| Cross Infection | 1 | 2004 | 94 | 0.050 |
Why?
|
| Bacteremia | 1 | 2004 | 89 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 1548 | 0.050 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2004 | 124 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2003 | 110 | 0.050 |
Why?
|
| Candidiasis | 1 | 2003 | 111 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2003 | 112 | 0.050 |
Why?
|
| Bone Diseases | 1 | 2003 | 96 | 0.050 |
Why?
|
| Adolescent | 2 | 2010 | 6443 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2020 | 11 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2010 | 6263 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 4102 | 0.040 |
Why?
|
| Outpatients | 1 | 2020 | 117 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 160 | 0.040 |
Why?
|
| Aged | 3 | 2007 | 9741 | 0.030 |
Why?
|
| Animals | 1 | 2010 | 13124 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 384 | 0.030 |
Why?
|
| Urine | 1 | 2011 | 24 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 32 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2007 | 1270 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 164 | 0.020 |
Why?
|
| Meningitis, Fungal | 1 | 2006 | 1 | 0.020 |
Why?
|
| Ethmoid Sinusitis | 1 | 2006 | 2 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 192 | 0.020 |
Why?
|
| Maxillary Sinusitis | 1 | 2006 | 10 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2006 | 32 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 370 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 269 | 0.020 |
Why?
|
| Blood-Borne Pathogens | 1 | 2004 | 7 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 900 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 978 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 74 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1372 | 0.010 |
Why?
|
| Candida | 1 | 2003 | 59 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 449 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 1452 | 0.010 |
Why?
|
| Catheterization | 1 | 2003 | 101 | 0.010 |
Why?
|
| Neutropenia | 1 | 2003 | 116 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2242 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 272 | 0.010 |
Why?
|
| Survival Rate | 1 | 2004 | 909 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 708 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 2749 | 0.010 |
Why?
|